1xbet 모바일 Pharmaceutical Co., Ltd.

Avanir Pharmaceuticals, Inc., an indirect, California-based subsidiary of 1xbet 모바일 Pharmaceutical Co., Ltd., has reached an agreement in principle to resolve the United States (U.S.) Department of Justice's investigation related to certain of Avanir's sales and marketing practices for its product NUEDEXTA^®(dextromethorphan HBr and qu1xbet 모바일id1xbet 모바일e sulfate) 20 mg/10 mg capsules prior to 2017. The agreement 1xbet 모바일 pr1xbet 모바일ciple between Avanir and the U.S. is cont1xbet 모바일gent upon the parties' negotiation and execution of civil, crim1xbet 모바일al and adm1xbet 모바일istrative agreements.

The impact on our parent company 1xbet 모바일 Holdings' 2018 financial results will be included in its fourth quarter earnings announcement and other relevant materials issued today.

Until the agreements with the government are finalized, 1xbet 모바일 will not be able to provide additional details. Avanir will provide more information regarding this matter once those agreements are executed.